August 8, 2015 Gregory J. Riely Memorial Sloan Kettering Cancer Center
Agenda •Modest Improvements for Management of “NSCLC” •Division of lung cancer by histology –Remains important in choosing initial therapy –Now less relevant in “2nd line” with immunotherapy •Division of lung cancer by mutations
Carboplatin/Paclitaxel +/- Bevacizumab Eligibility: • Stage IIIB (with pleural or pericardial effusion), stage IV NSCLC, or recurrent NSCLC • No prior chemo • PS 0-1 • Non-squamous NSCLC • No Hx of hemoptysis • No CNS metastases
Paclitaxel / Carboplatin q 3 weeks x 6 cycles
Paclitaxel / Carboplatin q 3 weeks x 6 cycles + Bevacizumab (15mg/kg q 3 wks) to PD
Sandler et al. N Engl J Med. 2006;355:2542
Carboplatin/Paclitaxel +/- Bevacizumab Response rate: 15% for carbo/paclitaxel 35% for carbo/paclitaxel + bevacizumab
